Finance

Lists
VX1:ETR
Vertex Pharmaceuticals Inc
€459.80
-0.03%
(-0.15) 1D
Aug 11, 5:35:52 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for VX1...
Open
€451.45
High
€460.25
Low
€451.45
Mkt. cap
134.12B
Avg. vol.
81.00
Volume
23.00
52-wk high
€464.00
52-wk low
€312.65
No. of employees
6K
Open
€451.45
High
€460.25
Low
€451.45
Mkt. cap
134.12B
Avg. vol.
81.00
Volume
23.00
52-wk high
€464.00
52-wk low
€312.65
No. of employees
6K
News stories
From web sources and news partners
Profile
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England. Wikipedia
About Vertex Pharmaceuticals Inc
CEOReshma Kewalramani
Employees6.4K
Founded1989
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitevrtx.com
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$4.73 / $4.75
-0.32%miss
Revenue / Est. (USD)
3.33B / 3.22B
+3.43%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.08B
3.19B
2.99B
3.33B
Cost of goods sold
1.39B
1.44B
1.35B
1.48B
Cost of revenue
1.39B
1.44B
1.35B
1.48B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
445.10M
487.00M
493.70M
582.20M
Operating expense
445.10M
487.00M
493.70M
582.20M
Total operating expenses
1.84B
1.93B
1.85B
2.07B
Operating income
1.24B
1.26B
1.14B
1.27B
Other non operating income
14.60M
-14.30M
-6.70M
46.20M
EBT including unusual items
1.30B
1.33B
1.25B
1.39B
EBT excluding unusual items
1.35B
1.38B
1.25B
1.42B
Income tax expense
215.90M
139.90M
221.50M
292.00M
Effective tax rate
16.62%
10.51%
17.68%
20.98%
Other operating expenses
-
-
-
-
Net income
1.08B
1.19B
1.03B
1.10B
Net profit margin
35.20%
37.34%
34.53%
32.99%
Earnings per share
4.80
5.03
4.47
4.73
Interest and investment income
125.70M
121.90M
114.80M
120.60M
Interest expense
-3.30M
-3.30M
-
-
Net interest expenses
122.40M
118.60M
114.80M
120.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.29B
1.29B
1.19B
1.33B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps